Skip to content
AnalystLens

Neurocrine Biosciences 8-K Report, Financial Results (Oct 28, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed October 28, 2025
Period End
October 28, 2025
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’19Jan ’19
  2. Leadership change8-K · May ’22May ’22
  3. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 8-K filed October 28, 2025. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. reported third-quarter 2025 financial results for the quarter ended September 30, 2025, in a press release attached as Exhibit 99.1 to this Form 8-K.

Total revenues were $794.9 milliona, compared with $622.1 million in the third quarter of 2024. Net product sales were $789.9 million, with INGREZZA net product sales of $686.6 million and CRENESSITY net product sales of $98.1 million. GAAP net income was $209.5 million, or $2.04 per diluted share, versus $129.8 million, or $1.24 per diluted share, a year earlier.

Non-GAAP net income was $222.1 millionb, or $2.17 per diluted share, compared with $189.2 million, or $1.81 per diluted share, in the prior-year quarter. GAAP R&D expense rose to $250.0 million from $195.0 million, and GAAP SG&A expense rose to $291.6 million from $234.3 million, reflecting investment in the osavampator and direclidine Phase 3 programs, CRENESSITY launch activities, and the INGREZZA sales team expansion. The company reaffirmed its full-year 2025 INGREZZA net product sales guidance of $2,500 million to $2,550 million and updated its GAAP R&D guidance to $1,000 million to $1,020 million and GAAP SG&A guidance to $1,140 million to $1,160 million.

Cash, cash equivalents, and marketable securities totaled $2,113.3 millionc at September 30, 2025, up from $1,815.6 million at December 31, 2024. The press release also highlighted clinical and corporate developments, including the start of a second Phase 3 registrational trial for direclidine in schizophrenia, new Phase 2 SAVITRI data for osavampator in major depressive disorder, a planned expansion of the INGREZZA and CRENESSITY sales teams to be completed by the end of the first quarter of 2026, and an R&D Day scheduled for December 16, 2025.

Key Highlights

  1. Total revenues of $794.9 million in Q3 2025, up from $622.1 million in Q3 2024.
  2. CRENESSITY net product sales of $98.1 million in Q3 2025, with 540 total new patient enrollment start forms in the quarter.
  3. INGREZZA net product sales of $686.6 million in Q3 2025, up from $612.9 million in Q3 2024.
  4. GAAP diluted EPS of $2.04 vs. $1.24 a year earlier; non-GAAP diluted EPS of $2.17 vs. $1.81.
  5. Full-year 2025 INGREZZA net product sales guidance reaffirmed at $2,500 million to $2,550 million.
  6. Updated full-year 2025 GAAP R&D guidance of $1,000 million to $1,020 million and GAAP SG&A guidance of $1,140 million to $1,160 million, including R&D milestone expense of $62 million tied to collaborations with Takeda and Nxera.
  7. Cash, cash equivalents, and marketable securities of $2,113.3 million at September 30, 2025; the company plans to expand its INGREZZA and CRENESSITY sales teams by the end of Q1 2026.

Frequently Asked Questions

  1. How did Neurocrine's revenue and earnings perform in the third quarter of 2025?

    Total revenues were $794.9 million, compared with $622.1 million in Q3 2024. GAAP net income was $209.5 million ($2.04 per diluted share), up from $129.8 million ($1.24 per diluted share). Non-GAAP net income was $222.1 million ($2.17 per diluted share), up from $189.2 million ($1.81 per diluted share).

  2. What drove the growth in product sales?

    INGREZZA net product sales were $686.6 million, up from $612.9 million a year earlier, with the press release citing double-digit volume growth and record quarterly new and total prescriptions. CRENESSITY, which had no sales in Q3 2024, generated $98.1 million in Q3 2025, with 80% reimbursement coverage for dispensed scripts.

  3. What is the company's full-year 2025 guidance?

    Neurocrine reaffirmed INGREZZA net product sales guidance of $2,500 million to $2,550 million. It updated GAAP R&D expense guidance to $1,000 million to $1,020 million and GAAP SG&A expense guidance to $1,140 million to $1,160 million. The R&D guidance includes $62 million of expense for development milestones.

  4. What are the key pipeline and corporate developments?

    The company initiated a second Phase 3 registrational trial for direclidine in adults with schizophrenia and presented Phase 2 SAVITRI data showing statistically significant and clinically meaningful improvement in depression severity for osavampator at 1 mg once daily. It also announced the appointment of Mike Sibley as Senior Vice President and General Manager of the Neuropsychiatry franchise and plans to host an R&D Day on December 16, 2025.

  5. What is the company's cash position?

    Cash, cash equivalents, and marketable securities totaled $2,113.3 million at September 30, 2025, up from $1,815.6 million at December 31, 2024.